Why the study?
The cellular and molecular mechanisms of action of the ActRIIA-Fc fusion protein sotatercept in pulmonary arterial hypertension were incompletely understood.
Does ActRIIA-Fc (sotatercept analog) suppress inflammation and reverse disease progression in experimental rodent models of pulmonary arterial hypertension?
Does ActRIIA-Fc (sotatercept analog) suppress inflammation and reverse disease progression in experimental rodent models of pulmonary arterial hypertension?
ActRIIA-Fc (sotatercept analog) demonstrates therapeutic anti-inflammatory and anti-proliferative activities that reverse cardiopulmonary remodeling in experimental models of PAH, providing a mechanistic basis for its clinical efficacy.
No takes yet. Share an insight, caveat, or question.
ActRIIA-Fc reverses experimental PAH remodeling; hypothesis-generating for sotatercept analogs, human trials needed before practice change.
Joshi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: